• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Iranian Journal of Reproductive Medicine >COMPARISON OF ORAL DYDROGESTERONE WITH SUPPOSITORY VAGINAL PROGESTERONE FOR LUTEAL-PHASE SUPPORT IN IN VITRO FERTILIZATION (IVF): A RANDOMIZED CLINICAL TRIAL
【24h】

COMPARISON OF ORAL DYDROGESTERONE WITH SUPPOSITORY VAGINAL PROGESTERONE FOR LUTEAL-PHASE SUPPORT IN IN VITRO FERTILIZATION (IVF): A RANDOMIZED CLINICAL TRIAL

机译：口服异孕酮与阴道阴道孕酮用于体外受精（IVF）时黄体支持的比较：随机临床试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Luteal phase support is mandatory in assisted reproductive technologies (ART) for optimizing outcome, so the luteal phase is supported with either progesterone, addition of estradiol to progesterone, hCG or gonadotropin releasing hormone (GnRH) agonists. Supplementation of luteal phase with progesterone is prescribed for women undergoing routine IVF treatment.Objective: To compare oral dydrogestrone with vaginal progesterone for luteal-phase support in IVF.Materials and Methods: We performed this prospective, randomized trial in a tertiary infertility care unit in Taleghani Hospital, Tehran, Iran. In total 80 Women with a history of male factor infertility undergoing controlled ovarian stimulation for IVF treatment (fresh cycle) randomly were divided in two groups (group A or oral dydrogesterone group and group B or vaginal progesterone group). The inclusion criteria were the use of GnRH analogue down-regulation and age less than 40 years old with regular menstrual cycles. All women were euthyroid and normoprolactinemic. Group A (n=40) received 10 mg dydrogesterone QID (40mg daily) and group B (n=40) received 400 mg suppository vaginal progesterone (cyclogest) twice per day (800 mg daily).Results: Clinical pregnancy rate in cyclogest group was higher than dydrogesterone group but the difference was not significant (p=0.52), furthermore the miscarriage rate in two group was the same. The difference between two groups regarding antral follicle, embryo number, luteal-phase duration, endometrial thickness, oocyte number and metaphase-II was not significant (p0.05).Conclusion: The results showed that oral dydrogesterone is as effective as vaginal progesterone for luteal-phase support in women undergoing IVF.
机译：背景：黄体期支持在辅助生殖技术（ART）中是必需的，以优化结果，因此黄体期可通过孕激素，在孕酮中添加雌二醇，hCG或促性腺激素释放激素（GnRH）激动剂来支持。对于接受常规IVF治疗的女性，处方黄体酮补充黄体酮。目的：比较口服dydrogestrone和阴道黄体酮在IVF中对黄体期的支持。材料和方法：我们在美国不孕不育治疗单位进行了这项前瞻性，随机试验。伊朗德黑兰Taleghani医院。将总共​​80名有男性因子不育病史并接受受控卵巢刺激以进行IVF治疗（新鲜周期）的女性随机分为两组（A组或口服孕激素组，B组或阴道孕激素组）。纳入标准为使用GnRH类似物下调且年龄小于40岁且月经周期正常。所有妇女均正常甲状腺和正常泌乳素。 A组（n = 40）接受10 mg dydrogesterone QID（每日40mg），B组（n = 40）每天接受400 mg栓剂阴道孕酮（cyclogest）每天两次（每日800 mg）。结果：Cyclgest组的临床妊娠率高于孕酮组，但差异无统计学意义（p = 0.52），而且两组的流产率相同。两组在肛门卵泡，胚胎数量，黄体期持续时间，子宫内膜厚度，卵母细胞数量和中期II方面的差异均无统计学意义（p> 0.05）。结论：口服dydrogrogesterone与阴道孕酮效果相同接受试管婴儿的妇女的黄体期支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号